Drug Trial Radar · NCT07002905
A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related Comorbidities
Last checked: Nov 19, 2026Latest source record: Dec 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
125
Actual
Start
Jul 3, 2025
Primary completion
Dec 8, 2025
Study completion Dec 8, 2025
Sponsor
- Lead sponsor
- Ascletis Pharma (China) Co., LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jun 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized, double-blind, placebo-controlled phase IIa study is designed to evaluate the efficacy, safety, and tolerability of ASC30 Tablets and ASC30 Tablets A1.
Conditions
- Chronic Weight Management
Interventions
ASC30 tablets or ASC30 tablets A1 or placeboDrug
Drug: ASC30 tablets or ASC30 tablets A1 administered orally daily Drug: Placebo administered orally daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change in body weight from Baseline up to Week 13Time frame: Baseline and Week 13
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Ascletis Clinical Site
Rogers, Arkansas
Ascletis Clinical Site
Fort Myers, Florida
Ascletis Clinical Site
Miami, Florida
Ascletis Clinical Site
Columbus, Ohio
Ascletis Clinical Site
Bellaire, Texas
Ascletis Clinical Site
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.